← Browse by Condition
Medical Condition

epidermal growth factor receptor

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for epidermal growth factor receptor sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — epidermal growth factor receptor Clinical Trials

How many clinical trials are currently recruiting for epidermal growth factor receptor?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for epidermal growth factor receptor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for epidermal growth factor receptor?
epidermal growth factor receptor research spans Phase 1 (1 trial), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a epidermal growth factor receptor clinical trial?
Eligibility criteria for epidermal growth factor receptor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
2
Top Sponsors
Pusan National University Hospital 1 trial
Jonsson Comprehensive Cancer Center 1 trial

Recruiting Clinical Trials

NCT07073365 Phase 2
Recruiting
Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)
Enrollment
70 pts
Location
South Korea
Sponsor
Pusan National University Hosp...
View Trial →
NCT06059690 Phase 1, Phase 2
Recruiting
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
Enrollment
50 pts
Location
United States
Sponsor
Jonsson Comprehensive Cancer C...
View Trial →

Related Conditions

non small cell lung cancer (1) glioblastoma multiforme (1) glycolytic index (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology